Xspray Pharma AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was SEK 28.87 million compared to SEK 16.95 million a year ago. Basic loss per share from continuing operations was SEK 1.4 compared to SEK 0.89 a year ago. Diluted loss per share from continuing operations was SEK 1.4 compared to SEK 0.89 a year ago.
For the six months, net loss was SEK 47.8 million compared to SEK 30.86 million a year ago. Basic loss per share from continuing operations was SEK 2.31 compared to SEK 1.62 a year ago. Diluted loss per share from continuing operations was SEK 2.31 compared to SEK 1.62 a year ago.